National Securities initiated coverage on Genprex with a new price target
$GNPX
Biotechnology: Pharmaceutical Preparations
Health Care
National Securities initiated coverage of Genprex with a rating of Buy and set a new price target of $7.00
Save time and jump to the most important pieces.
National Securities initiated coverage of Genprex with a rating of Buy and set a new price target of $7.00
SC 13G/A - Genprex, Inc. (0001595248) (Subject)
SC 13G - Genprex, Inc. (0001595248) (Subject)
SC 13G - Genprex, Inc. (0001595248) (Subject)
SCHEDULE 13G - Genprex, Inc. (0001595248) (Subject)
8-K - Genprex, Inc. (0001595248) (Filer)
424B5 - Genprex, Inc. (0001595248) (Filer)
4 - Genprex, Inc. (0001595248) (Issuer)
4 - Genprex, Inc. (0001595248) (Issuer)
4 - Genprex, Inc. (0001595248) (Issuer)
AUSTIN, Texas, Jan. 6, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that members from its executive leadership team will be attending and participating in investor, industry and business development meetings at the 43rd Annual J.P. Morgan Healthcare Conference, taking place Jan. 13-16, 2025 in San Francisco, California. In attendance will be Ryan Confer, President, Chief Executive Officer and Chief Financi
Genprex Completes Phase 1 Dose Escalation Portion of Acclaim-3 Clinical Trial Results from Phase 1 Dose Escalation Demonstrate Favorable Safety Profile of REQORSA and Tecentriq in ES-SCLC Patients AUSTIN, Texas , Dec. 16, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has completed the Phase 1 dose escalation portion of the Acclaim-3 clinical trial of Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with Tecentriq® (atezolizumab) as maintenance therapy to treat patients with extensive stage small cell
License includes Genprex's Reqorsa® Gene Therapy in Combination with ALK-Inhibitors for the Potential Treatment of ALK-Positive Lung Cancer AUSTIN, Texas, Nov. 20, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive license agreement with the University of Michigan, granting Genprex a worldwide, exclusive license to the University's patent rights relating toits lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), in combination with ALK-inhibitors for the potential treatment of
Follows the Recent Appointment of Ryan Confer as Genprex President and CEO and to its Board of Directors AUSTIN, Texas, May 13, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Board of Directors has appointed Jose A. Moreno Toscano as non-executive Chairman of the Board following the sudden passing of the Company's co-founder and previous Chairman Rodney Varner. Prior to his appointment as Chairman,
Strengthens management team with seasoned regulatory expert to support pipeline of gene therapies for the treatment of cancer and diabetes, including two clinical trials in Non-Small Cell Lung Cancer and one in Small Cell Lung Cancer AUSTIN, Texas, Aug. 22, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the appointment of Suzanne Thornton-Jones, Ph.D. as Senior Vice President, Regulatory Affairs. Dr. Thornton-Jones will leverage her regulatory expertise to guide and oversee the Company's regulatory submissions and strategy